Photo Biomodulation Therapy for Alveolar Osteitis Recovery in Oral Contraceptive Users

NCT ID: NCT06865508

Last Updated: 2025-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-01

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

does laser effect on alveolar osteitis recovery in oral contraceptive users ?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

photo biomodulation therapy for alveolar osteitis recovery in oral contraceptive users

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alveolar Osteitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study is a randomized clinical trial (RCT) designed to evaluate the effectiveness of laser therapy combined with zinc oxide eugenol dressing in comparison to zinc oxide eugenol dressing alone in the management of dry socket among females using oral contraceptives. The study assessed outcomes related to pain, quality of life, and socket volume.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
double

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1. Experimental Group: Laser therapy combined with zinc oxide eugenol dressing.

* Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].
* Zinc oxide eugenol dressing was applied immediately before the laser therapy.
* The intervention will be performed at \[specified intervals every day 0, day7, day 14, day 30)\]

Group Type EXPERIMENTAL

Laser therapy

Intervention Type DEVICE

Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].

zinc oxide eugenol dressing.

Intervention Type DEVICE

zinc oxide eugenol dressing.

control group

zinc oxide eugenol dressing.

Group Type ACTIVE_COMPARATOR

zinc oxide eugenol dressing.

Intervention Type DEVICE

zinc oxide eugenol dressing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laser therapy

Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].

Intervention Type DEVICE

zinc oxide eugenol dressing.

zinc oxide eugenol dressing.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Female patients aged 25-40 years. Currently using oral contraceptives for at least 3 months prior to participation.

Diagnosed with dry socket (alveolar osteitis) based on clinical criteria.

Exclusion Criteria

Presence of systemic diseases (e.g., diabetes, immunodeficiency disorders). Smoking or tobacco use. Allergies to zinc oxide or other study materials. Use of antibiotics or anti-inflammatory medications within the last 2 weeks. Pregnancy or breastfeeding.
Minimum Eligible Age

25 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Badr University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Doaa Saeed Mohamed

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

physical therapy at Badr University in Cairo(BUC)

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BUC-IACUC-231015-38

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.